ABSTRACT
BACKGROUND: ABO incompatible (ABOi) live-donor renal transplantation is a successful and accepted form of treatment for patients with renal failure. Although there is significant controversy as to how antiblood group antibodies should be removed and their resynthesis prevented, subsequent immunosuppressive regimes have all involved steroids. We and other groups have successfully used steroid sparing regimes for conventional ABO compatible transplantation and this study describes the use of our steroid sparing protocol in ABOi transplantation. METHODS: We have transplanted 10 ABOi patients using 1 week of steroids (prednisolone 1 mg/kg for 4 days, 0.5 mg/kg for 3 days and then stopped), tacrolimus and mycophenolate mofetil. Steroids were reintroduced in the event of rejection. RESULTS: Patient- and allograft-survival 1 year posttransplantation is 100%. Three patients experienced antibody-mediated rejection within 2 weeks of transplantation, which was successfully reversed. There has been no late rejection. Allograft function was similar to our live-donor ABO compatible transplant patients receiving a similar steroid sparing regime (12-month mean creatinine 131+/-15 micromol/L vs. 138+/-48 micromol/L; mean CrCl 63.2+/-22 mL/min vs. 56.7+/-20 mL/min). CONCLUSIONS: This study shows that ABOi live-donor transplantation can be successfully accomplished using a steroid-sparing protocol.
Subject(s)
ABO Blood-Group System , Adrenal Cortex Hormones/therapeutic use , Blood Group Incompatibility , Kidney Transplantation/immunology , Adult , Drug Administration Schedule , Drug Therapy, Combination , Female , Humans , Immunosuppressive Agents/therapeutic use , Living Donors , Male , Middle Aged , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Patient Selection , Prednisolone/therapeutic use , Tacrolimus/therapeutic useABSTRACT
BACKGROUND: Compatibility testing is the standard protocol that identifies suitable blood for patients requiring transfusion. If the antibody screen is negative or no clinically significant antibodies are detected, BCSH guidelines and AABB standards allow an immediate-spin crossmatch (IS XM) or even electronic issue. The testing requirement is less clear where autoantibodies or non-clinically significant alloantibodies compromise the indirect antiglobulin test crossmatch (IAT XM). Performing an IAT XM will give a mismatched result anyway, delays the supply of blood to the patient, and provides no additional benefit or safety. STUDY DESIGN AND METHODS: From January 2002 to April 2006, the provision of blood for autoimmune hemolytic anemia (AIHA) patients with autoantibodies and no alloantibodies as well as patients with alloantibodies that exhibited a "high-titer, low-avidity" (HTLA) mode of reactivity was reviewed. RESULTS: A total of 222 AIHA patients (428 samples) with autoantibodies had 1585 units of red cells supplied after IAT XM; 1308 (82.5%) were mismatched. In 50 patients (80 samples) with HTLA-like antibodies, 286 units of 328 (87.2%) were mismatched by IAT XM. CONCLUSION: No adverse reactions were reported for the study groups where "suitable" blood was provided after a serologically mismatched IAT XM. No additional benefit for these patients can be claimed by performing an IAT XM over an IS XM, as a check of ABO match. The IAT XM is both costly and time-consuming. It is proposed that for these study group patients, a reduction to an IS XM can be applied and can be beneficial.
